Secukinumab in Polymyalgia Rheumatica: Results of the Phase 3 REPLENISH Trial - Report from EULAR 2026

Dr. Christian Dejaco presents highly anticipated data from the Phase 3 REPLENISH trial, evaluating the efficacy and safety of secukinumab in patients with Polymyalgia Rheumatica (PMR), highlighted at the EULAR 2026 Congress. This breakthrough recap examines how targeting the IL-17A pathway provides a powerful steroid-sparing therapeutic alternative, significantly improving clinical remission rates while reducing the burden of glucocorticoid-related side effects.Video: https://medicaldigest.org/scientific-contents/interview:secukinumab-polymyalgia-rheumatica-results-phase-3-replenish-trial